Institutional investors purchased a net $2.2 million shares of THRX during the quarter ended September 2014. This may signal that the smart money is gaining interest in this company as the 83.32% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 3.2 Million shares of Theravance Inc
LITESPEED MANAGEMENT LLC Bought 2.7 Million shares of Theravance Inc